News Agency
The Times

MAIWEIJIAN, First Approved Biosimilar of Denosumab (120mg) in China

  • Written by PR Newswire

SHANGHAI, April 8, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that Denosumab Injection (trade name: MAIWEIJIAN, R&D code: 9MW0321) developed by its wholly-owned subsidiary T-mab has officially obtained the marketing authorization approval by National Medical...

Read more: MAIWEIJIAN, First Approved Biosimilar of Denosumab (120mg) in China

Why Headless CMS Is Ideal for Scalable Digital Sales Experiences

Digital sales experiences have become a major part of how buyers discover, evaluate, and choose products or services. Buyers no longer rely only on direct conversations with sales representatives. They interact with websites, product pages, landing pages, emails, digital sales... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion